Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53 - Wikidata - wikimedia - TriplyDB

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53

http://www.wikidata.org/entity/Q36238650

about

Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma Recent progress in pancreatic cancer Trial watch - inhibiting PARP enzymes for anticancer therapy DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer Targeting ATM-deficient CLL through interference with DNA repair pathways Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.Whole-exome sequencing of pancreatic neoplasms with acinar differentiation Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC.Do mantle cell lymphomas have an 'Achilles heel'?Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.Development of synthetic lethality anticancer therapeutics.Tug of war between survival and death: exploring ATM function in cancer.Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes Pathological and molecular evaluation of pancreatic neoplasms.Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.Predicting PARP inhibitor sensitivity and resistance.ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation Molecular predictors of locoregional and distant metastases in oropharyngeal squamous cell carcinoma.DNA repair in cancer: emerging targets for personalized therapy.Gene mutations and actionable genetic lesions in mantle cell lymphoma.ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib.PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas.Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.Reprogramming cellular events by poly(ADP-ribose)-binding proteins Detection and repair of ionizing radiation-induced DNA double strand breaks: new developments in nonhomologous end joining.The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment.The genetic classification of pancreatic neoplasia.Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.Novel targets for ATM-deficient malignancies.PARP1 expression in mantle cell lymphoma: the utility of PARP1 immunohistochemistry and its relationship with markers of DNA damage.ATM, THMS, and RRM1 protein expression in nasopharyngeal carcinomas treated with curative intent.Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma.

P2860

Q21129230-BEC64602-C07D-4781-9B50-6A2F7AC5331C Q24626346-1817BAED-EEC4-487F-8D5C-C13337A1F654 Q26745673-C8E9E5D9-0ADD-4408-8F88-4FF2153C3796 Q26776513-74D52238-FFC7-49E9-B99C-63E2A2CD349B Q26822592-70434DB3-30DB-4846-867B-F135FADA62A3 Q27853007-593908D2-9E8B-4B79-A4AB-C363D5F1BCB3 Q33720718-7ED5661A-5DFE-477B-9519-4CF9C4CAE1F0 Q33888782-824B7D97-19B5-40EB-BB10-9EA41D64EEDD Q34090009-C812CBC9-6796-4573-A7F5-DDB9C82E70B2 Q34309488-939837E2-EF57-4C57-9139-93BACBC322D9 Q34380368-3619C66A-E7F3-42F8-89C3-E554AD674B30 Q35134937-93E6EA4A-6AB8-4D1A-BED8-6C5E8EC2F076 Q35160677-4D66A970-27E0-4BC3-B594-4A8F470FC5DF Q35670143-1F0C9373-2C9D-4E94-835D-BD1523DB72A0 Q35676851-71420938-A029-4D73-9CC4-A83B049F424F Q35895214-E7500774-B48C-42BB-87CF-F7826DDC249E Q36129160-FCD72DBC-3184-4678-BEC0-793ACADD6F49 Q36294441-30BA3C26-5CBE-4A33-B880-CB175D7446F9 Q36472222-548D8294-821C-4B35-858E-2C7C9083D29E Q36941509-22FEF1E7-5D72-4689-9641-17F4E740F8A7 Q37283961-596CA553-8EF6-459F-8EDC-077234D08AE1 Q37600799-43E56B77-C8AA-447E-A6E0-F0070C886DF9 Q37629080-087C104C-9B6F-4EC9-862B-30577D42602A Q37633188-E47C542D-64C0-4B49-913D-BB30A92A0069 Q37633440-A83EF8C8-D968-46D1-9586-3D37ABED7E01 Q37678950-CA5CF132-A9CB-4574-B6A6-3B3F78B21D08 Q37726508-4EB1D837-CC56-458F-8DDE-6DBEAA8AA186 Q38069879-9DCE6942-E86E-4131-9D51-F480AF78CC7A Q38083939-FBBAAD74-A8E2-4533-9580-76F57A78420E Q38142158-AAB486BA-2DEE-4312-BA25-4D24A985DB54 Q38293619-E530C7FA-DA75-4537-A1C0-A9FDFE7265F9 Q38326191-B3F3646B-A770-42F5-8EFF-D7CEB36C1B62 Q38675161-771CE55C-7C4A-42EE-9AFA-B175B7F51D9A Q38740969-59C5AD71-D67F-4C37-88BB-642DC5415D48 Q38780396-8FE96B28-AC45-44DA-A925-15834214176F Q38840443-CE254825-7D28-4BAF-8B0B-DA030EF0947D Q38866642-BAF56586-47B7-4369-B743-BAB50CD83C3C Q39142155-F8957845-B233-4A8A-A460-45F0E55EDA6D Q40254033-C5E7128F-06D9-491A-8EC1-9B41AB9CB401 Q41269380-2FFC927C-1FE8-4050-B2DD-4A8DC89CEE35

P2860

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53

http://www.wikidata.org/entity/Q36238650

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Enhanced cytotoxicity of PARP ...... mutations in both ATM and p53

@ast

Enhanced cytotoxicity of PARP ...... mutations in both ATM and p53

@en

type

label

Enhanced cytotoxicity of PARP ...... mutations in both ATM and p53

@ast

Enhanced cytotoxicity of PARP ...... mutations in both ATM and p53

@en

prefLabel

Enhanced cytotoxicity of PARP ...... mutations in both ATM and p53

@ast

Enhanced cytotoxicity of PARP ...... mutations in both ATM and p53

@en

P1433

Q36238650-8BCEF906-DE2F-4048-9E89-025BC69179CD

P1476

Q36238650-593F7135-C0EA-4BD1-8FFB-083BDBD4E56F

P2093

Q36238650-08FE6F2E-7787-4C00-BF7B-3B3BC2AB5C38

Q36238650-09AB577A-39CA-47E2-9524-A127D66016FE

Q36238650-0A14D425-7F84-4782-B029-39837986A64A

Q36238650-0A28B919-1804-4D05-A151-C60D09EE51F0

Q36238650-13619D39-09EB-450C-B37E-D38D4561B259

Q36238650-47DC2D89-3860-41F6-A887-92D003D12994

Q36238650-54E7981D-C184-4157-9768-BD9C5081BFEC

Q36238650-6C93730B-5EFF-43C4-8F47-CB5487F5935D

Q36238650-95EE2EF1-6A38-4A71-AE6E-24CCD0019158

Q36238650-A22FA919-B9BD-467F-8503-A84443622933

P2860

Q36238650-00E15DCA-C906-483B-8E74-FB851F0FE822

Q36238650-09B5CFBB-D071-47FB-B981-EAEF4A885DD9

Q36238650-0D07B61F-77E4-44F2-9826-749B953B9A6E

Q36238650-105C0B59-384E-4F18-BFB5-3FF10AFD05EB

Q36238650-17B0F7CB-D7B0-4EFD-83DB-E13C6BCFFCB0

Q36238650-251DE872-2361-48CB-8C99-3018A1783652

Q36238650-2D7C984F-5D25-46EB-9B90-BD50D2789FE6

Q36238650-310E81D1-FB7A-4C01-B21C-ABF084BAF137

Q36238650-34229368-5038-4195-BA69-4CF78B285327

Q36238650-3B50E80F-A55D-4F05-8C0F-06F97EA51615

P304

Q36238650-BD0320B7-E66F-409F-942A-F61C56493DCD

P31

Q36238650-C66609C7-57A4-4822-8C95-A3693C317499

P356

Q36238650-083DB091-21C7-4318-874E-EFBFAE585BA5

P433

Q36238650-EFB40118-2BB3-48AA-9EAA-4916230FC3FD

P478

Q36238650-01A29E2F-7EBB-4357-B27F-1EFC6E68EB24

P577

Q36238650-BA6B6F44-3432-4021-94D6-D2D5C0B247A2

P5875

Q36238650-DEB8A60A-FD5F-4434-9EB7-51F3F018BE16

P698

Q36238650-6F7054B2-C589-4A1D-94E6-C2330CB867AE

P921

Q36238650-5273B8CE-54E4-4803-BAA4-9652E11BEEE7

P932

Q36238650-B6ADA4E7-FD38-4832-8D1D-3B8EE19C9302

P356

P1433

EMBO Molecular Medicine

P1476

Enhanced cytotoxicity of PARP ...... mutations in both ATM and p53

@en

P2093

Alexander Klimowicz

http://www.w3.org/2001/XMLSchema#string

Anthony M Magliocco

http://www.w3.org/2001/XMLSchema#string

Bruce C McKay

http://www.w3.org/2001/XMLSchema#string

Chris T Williamson

http://www.w3.org/2001/XMLSchema#string

D Gwyn Bebb

http://www.w3.org/2001/XMLSchema#string

David Gilley

http://www.w3.org/2001/XMLSchema#string

Eiji Kubota

http://www.w3.org/2001/XMLSchema#string

Huong Muzik

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Hamill

http://www.w3.org/2001/XMLSchema#string

LiRen Tu

http://www.w3.org/2001/XMLSchema#string

P2860

The DNA-damage response in human biology and disease

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Somatic mutations affect key pathways in lung adenocarcinoma

Essential role for DNA-PKcs in DNA double-strand break repair and apoptosis in ATM-deficient lymphocytes

The combined status of ATM and p53 link tumor development with therapeutic response

Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Identification of in vitro and in vivo phosphorylation sites in the catalytic subunit of the DNA-dependent protein kinase.

P304

515-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EMMM.201200229

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221893950

http://www.w3.org/2001/XMLSchema#string

P698

22416035

http://www.w3.org/2001/XMLSchema#string

P921

P932

3443945

http://www.w3.org/2001/XMLSchema#string